• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

    3/10/25 10:13:07 AM ET
    $GMAB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GMAB alert in real time by email

    Company Announcement

    • Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38
    • Genmab will not pursue further clinical development of HexaBody-CD38
    • Data validates clinical potential of the HexaBody platform
    • Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT

    COPENHAGEN, Denmark; March 10, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a thorough evaluation of the data, the market landscape, and Genmab's rigorous portfolio prioritization, Genmab will not pursue further clinical development of HexaBody-CD38.

    "While we are disappointed that J&J has decided not to advance HexaBody-CD38, the data confirms the clinical potential of the HexaBody platform, reinforcing its value for future applications," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab. "With EPKINLY® (epcoritamab) moving from strength to strength and two wholly owned assets, rinatabart sesutecan (Rina-S™) and acasunlimab in Phase 3 development, we are confident in the potential of our existing pipeline of innovative antibody therapeutics. Genmab intends to maintain its laser sharp focus on and disciplined investments in our promising late-stage proprietary clinical pipeline and continues to execute against our capital allocation framework ensuring future growth."

    As stipulated by the development and option agreement between Genmab and J&J for HexaBody-CD38, Genmab provided J&J with data from a clinical proof-of-concept study in multiple myeloma, including a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj).

    The Phase 2 expansion Part B of the study assessed the objective response rate (primary endpoint) of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody- naïve relapsed or refractory multiple myeloma.

    Preliminary data submitted by Genmab to J&J, inclusive of 88 patients who received a study treatment and 84 patients who were response evaluable (42 in each arm), demonstrated an overall response rate (ORR) of 55% (95% CI: 39%, 70%) in the HexaBoby-CD38 IV arm vs. 52% in the daratumumab SC arm (95% CI: 36%, 68%); very good partial response (VGPR) or better rate was 29% vs. 17%; and complete response (CR) or better rate was 7% vs. 2%.

    Due to the relatively short follow-up time, secondary efficacy endpoints including duration of response, progression-free survival, and overall survival were not mature yet. Treatment emergent Adverse events (TEAEs) above 20% in the Hexabody-CD38 arm were neutropenia, infusion related reactions, anemia, and thrombocytopenia. No new safety findings were observed in the daratumumab arm of the study. TEAEs leading to death included one patient in the HexaBody-CD38 IV arm and two patients in the daratumumab SC arm; none of these deaths was related to the study treatment. Follow-up is ongoing and more mature data will be presented at a future medical conference.

    This news does not impact Genmab's 2025 Financial Guidance.

    Conference Call Details

    Genmab will host a conference call to discuss this event today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT. To join the call or listen to the webcast, please register using the following link: https://genmab-investor-update-mar2025.open-exchange.net/.

    An archived webcast of the call will be available at https://www.genmab.com/investor-relations.

    About the 3014-01 Trial

    3014-01 is a Phase 1/2, open-label, multi-center trial to evaluate the safety and preliminary efficacy of HexaBody-CD38 as a monotherapy in patients with relapsed or refractory multiple myeloma and other blood cancers. The trial consists of three parts: a dose-escalation phase (Phase 1) and an expansion phase (Part A and Part B). The primary objective of Phase 1 is to determine the recommended Phase 2 dose and the maximum tolerated dose as well as establish the safety profile of HexaBody-CD38 monotherapy. The purpose of Phase 2 Expansion Part A is to assess the objective response rate of HexaBody-CD38 for patients with relapsed or refractory multiple myeloma and other blood cancers. The purpose of Phase 2 Expansion Part B is to assess the objective response rate of HexaBody-CD38 versus subcutaneous daratumumab in patients with CD38 antibody naïve relapsed or refractory multiple myeloma. More information on this trial can be found at https://www.clinicaltrials.gov (NCT04824794).

    About Genmab 

    Genmab is an international biotechnology company with a core purpose of guiding its unstoppable team to strive toward improving the lives of patients with innovative and differentiated antibody therapeutics. For more than 25 years, its passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative and data sciences, resulting in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators and effector function-enhanced antibodies. By 2030, Genmab's vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO) antibody medicines®. 

    Established in 1999, Genmab is headquartered in Copenhagen, Denmark, with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com and follow us on LinkedIn and X.



    Contact:        

    Marisol Peron, Senior Vice President, Global Communications & Corporate Affairs

    T: +1 609 524 0065; E: [email protected]

    Andrew Carlsen, Vice President, Head of Investor Relations

    T: +45 3377 9558; E: [email protected]



    This Company Announcement contains forward looking statements. The words "believe," "expect," "anticipate," "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with preclinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab's most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.



    Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; HexaBody®; DuoHexaBody®, HexElect® and KYSO®. DARZALEX FASPRO® is a trademark of Johnson & Johnson. EPKINLY® and its design is a trademark of AbbVie Biotechnology Ltd. Rina-S™ is a trademark of ProfoundBio, US Co. and ProfoundBio (Suzhou) Co., Ltd.

    Company Announcement no. 09

    CVR no. 2102 3884

    LEI Code 529900MTJPDPE4MHJ122

    Genmab A/S

    Carl Jacobsens Vej 30

    2500 Valby

    Denmark

    Attachment

    • 10032025_CA09_JNJ Decision GEN3014


    Primary Logo

    Get the next $GMAB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GMAB

    DatePrice TargetRatingAnalyst
    4/1/2025Mkt Perform → Underperform
    Bernstein
    3/11/2025Mkt Perform → Outperform
    William Blair
    2/13/2025$27.00Market Perform → Outperform
    Leerink Partners
    10/8/2024Buy
    Redburn Atlantic
    9/4/2024$31.00Equal-Weight
    Morgan Stanley
    8/20/2024Overweight → Neutral
    JP Morgan
    7/15/2024Sector Perform → Outperform
    RBC Capital Mkts
    2/23/2024$46.00 → $48.00Market Perform → Outperform
    BMO Capital Markets
    More analyst ratings

    $GMAB
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

      Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trial Full results from the trial will be submitted for presentation at an upcoming medical conference in 2025 Genmab A/S (NASDAQ:GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL), following at least one pr

      5/1/25 8:24:00 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

      Company Announcement Decision to submit based on a positive overall response rate (ORR) (p-value < 0.0001), one of the dual primary endpoints in the Phase 3 EPCORE® FL-1 trialFull results from the trial will be submitted for presentation at an upcoming medical conference in 2025 COPENHAGEN, Denmark; May 2, 2024 – Genmab A/S (NASDAQ:GMAB) announced today its intention to submit in the first half of 2025 a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for subcutaneous epcoritamab, a bispecific antibody being investigated in combination with rituximab and lenalidomide (R2) for the treatment of adult patients with relapsed or refractory (R/R

      5/1/25 8:14:12 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2025

      Company Announcement Net sales of DARZALEX® in the first quarter of 2025 totaled USD 3,237 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.) COPENHAGEN, Denmark; April 15, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J were USD 3,237 million in the first quarter of 2025. Net trade sales were USD 1,829 million in the U.S. and USD 1,409 million in the rest of the world. Genmab receives royalties on the wo

      4/15/25 6:21:58 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Genmab A/S (Amendment)

      SC 13G/A - GENMAB A/S (0001434265) (Subject)

      2/8/24 10:03:08 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Genmab A/S (Amendment)

      SC 13G/A - GENMAB A/S (0001434265) (Subject)

      2/2/24 2:18:06 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Genmab A/S

      SC 13G - GENMAB A/S (0001434265) (Subject)

      2/6/23 2:36:15 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    SEC Filings

    See more
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      5/8/25 11:19:36 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      5/5/25 11:05:13 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Genmab A/S

      6-K - GENMAB A/S (0001434265) (Filer)

      5/1/25 8:21:13 PM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Financials

    Live finance-specific insights

    See more
    • Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

      Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38 Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising and showed robust clinical efficacy, following a

      3/10/25 10:21:00 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

      Company Announcement Johnson & Johnson has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 Genmab will not pursue further clinical development of HexaBody-CD38Data validates clinical potential of the HexaBody platform Genmab to host a conference call today at 5:00 PM CET / 4:00 PM GMT / 12:00 PM EDT COPENHAGEN, Denmark; March 10, 2025 – Genmab A/S (NASDAQ:GMAB) announced today that Johnson & Johnson (J&J) has decided that it will not exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38 (GEN3014). While the initial HexaBody-CD38 clinical data is promising

      3/10/25 10:13:07 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab Publishes 2024 Annual Report

      Company Announcement COPENHAGEN, Denmark; February 12, 2025 – Genmab A/S (NASDAQ:GMAB) announced today the publication of its Annual Report for 2024. Below is a summary of business progress in 2024, financial performance for the year and the financial outlook for 2025. The full report is attached as a PDF file and in iXBRL format and can be found in the investor section of the company's website, www.genmab.com/investor-relations. Conference CallGenmab will hold a conference call to discuss the full year results for 2024 today, February 12, 2025, at 6:00 pm CET, 5:00 pm GMT, 12:00 pm EST. To join the call please use the below registration link. Registered participants will receive an email

      2/12/25 11:01:37 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Leadership Updates

    Live Leadership Updates

    See more
    • Genmab Announces Appointment of Tahamtan Ahmadi to Newly Created Position of Chief Medical Officer, Head of Experimental Medicines

      Company Announcement COPENHAGEN, Denmark; February 22, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that Tahamtan Ahmadi, M.D., Ph.D., has been appointed to the newly created position of Executive Vice President and Chief Medical Officer, Head of Experimental Medicines effective March 1, 2021. Dr. Tahi Ahmadi joined Genmab in 2017 and previously served as Genmab’s Senior Vice President, Head of Oncology. In this new role, Dr. Ahmadi will lead research, discovery, regulatory and medical activities. He joins the Executive Management Team of Chief Executive Officer Dr. Jan van de Winkel, Chief Development Officer Dr. Judith Klimovsky, Chief Financial Officer Anthony Pagano, and Chief Opera

      2/22/21 8:00:51 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $GMAB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Genmab downgraded by Bernstein

      Bernstein downgraded Genmab from Mkt Perform to Underperform

      4/1/25 9:01:35 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab upgraded by William Blair

      William Blair upgraded Genmab from Mkt Perform to Outperform

      3/11/25 7:35:51 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Genmab upgraded by Leerink Partners with a new price target

      Leerink Partners upgraded Genmab from Market Perform to Outperform and set a new price target of $27.00

      2/13/25 7:09:15 AM ET
      $GMAB
      Biotechnology: Pharmaceutical Preparations
      Health Care